Description: Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland.
Home Page: www.bachem.com
Hauptstrasse 144
Bubendorf,
4416
Switzerland
Phone:
41 58 595 2021
Officers
| Name | Title |
|---|---|
| Mr. Thomas Meier | CEO, COO & Chairman of Group Executive Board |
| Mr. Alain Schaffter | Chief Financial Officer |
| Mr. Michael Suter | Vice President of Global Accounting |
| Dr. Gunther Loidl | Chief Technology Officer |
| Mr. Achim Pluckebaum | Chief Information Officer |
| Dr. Daniel Grotzky | Head of Group Communications |
| Viviane Minden | Chief Human Resources Officer |
| Dr. Anne-Kathrin Stoller Ph.D. | Chief Operating Officer of Bachem Americas, Inc. |
| Dr. Torsten Wohr | Chief Commercial Officer |
| Mr. Boris Corpataux | VP & Head Global Strategic Alliances |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Materials |
|---|---|
| GIC Group: | Materials |
| GIC Industry: | Chemicals |
| GIC Sub-Industry: | Commodity Chemicals |
| Forward PE: | 42.9185 |
|---|---|
| Trailing PE: | 53.3565 |
| Price-to-Book MRQ: | 3.7747 |
| Price-to-Sales TTM: | 11.942 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2009 |